The State Drug Affordability Board Is Watching Patent Listings You Haven’t Checked in a Year
On July 1, 2026, a federal judge in Denver blocked Colorado’s price cap on Enbrel. The board that set the
The Forum You File In Changes Your Odds More Than the Merits Do
In 2015, a Delaware federal judge looked at prior art covering an antioxidant added to a rivastigmine skin patch and
The Forum You File In Changes Your Odds More Than the Merits Do Read Post »
Why Your PBM’s Generic Substitution Policy Is Six Months Behind the Actual Patent Timeline
The Short Answer Six months is the optimistic case. When Amgen launched the first Humira biosimilar on January 31, 2023,
The Territoriality Trap: Why a US Patent Win Means Nothing Where the Molecule Was Never Filed
On October 2, 2023, the Patent Trial and Appeal Board refused to institute Mylan’s inter partes review of two Novo
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US
On October 16, 2018, adalimumab biosimilars went on sale across Germany, France and the rest of the European Union. On
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US Read Post »
Your 340B Contract Pharmacy Network Is Working Off a Different Generic Entry Date Than Your Legal Team
DrugPatentWatch tracks generic entry dates for a living, and one pattern shows up over and over in support calls from
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose
A drug that never reaches patients usually did not fail a safety test. In a systematic review of 115 published
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose Read Post »
Three Clocks, One Patent: The Extension Gap Between Australia, Canada, and the EU
Abilify Maintena lost its patent-based market exclusivity in the European Union and the United States in October 2024 [1][2]. In
Three Clocks, One Patent: The Extension Gap Between Australia, Canada, and the EU Read Post »
Someone Else Found a New Use for Your Drug. Here’s What Happens Next.
In 2006, a Boston jury ordered Eli Lilly to pay roughly $65 million in back royalties, plus a 2.3% running
Someone Else Found a New Use for Your Drug. Here’s What Happens Next. Read Post »
